Alzheimer’s drugs eyed as next big obesity-like opportunity
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
verywellhealth8h
What Happens to Your Brain When You Take These 16 Supplements?
While many people take supplements for brain health, the research supporting supplemental nutrients' effects on brain health ...
What Type of Doctor Treats Dementia and Cognitive Decline?
Learn about the types of providers who treat patients with age-related cognitive decline and dementia and how to get the most out of your initial visit.
Alzheimer’s Drugs Eyed by Investors Seeking Obesity-Like Gains
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Could Alzheimer’s treatment drugs be the next big investor opportunity after obesity pills?
Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the ...
Has Jim Cramer Lost Faith in Biogen Inc. (BIIB)’s Struggles with Alzheimer’s and MS Challenges?
We recently published a list of Jim Cramer Discussed These 10 NASDAQ 100 Stocks Recently. In this article, we are going to ...
China Medical System （00867）Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer’s Type
As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...
Death notices and funeral announcements in The Newcastle Chronicle last week
Died suddenly on 22nd December 2024. A dear son, beloved dad and brother. A funeral service will be held for Grant on ...
BioSpace4dOpinion
Opinion: The Cocktail Recipe That Will Cure Alzheimer’s
Effectively treating and preventing this common form of dementia will require a cocktail of drugs and a combination of ...
Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug
Novo Nordisk petitions the FDA to exclude liraglutide from the 503B Bulks List, citing safety risks, lack of clinical need, ...